CAH News | Roxom Stocks

Invest Private Security

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Preferreds paying dividends in bitcoin.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Everything Roxom publishes, in one feed.

Product launches, listings, and company news.

Commentary and analysis from the Roxom team.

Research Reports

In-depth research on bitcoin capital markets.

Weekly market updates, delivered to your inbox.

Roxom in the news, and press resources.

Where to find us, online and in person.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CA

Mkt Cap

$52.41B

Volume

190.97K

Next Earnings

October 29th

Loading chart

CA

CAHCardinal Health, Inc.

CAH

Pay with—

Available Balance0.00

CA

Mkt Cap

$52.42B

Volume

192.91K

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.The Motley Fool · Sep 18, 2026

Is Nuveen ESG Mid-Cap Value ETF (NUMV) a Strong ETF Right Now?The article provides an analysis of the Nuveen ESG Mid-Cap Value ETF (NUMV), a smart beta ETF launched in 2016 with $442.53 million in assets. NUMV tracks the TIAA ESG USA Mid-Cap Value Index with a 0.31% expense ratio and has returned 11.92% year-to-date and 14.53% over the past year. The fund holds 89 companies with heaviest exposure to Financials (19.6%), Industrials, and Information Technology sectors. Alternative ESG ETFs like ESGV and ESGU are also mentioned as comparable options.Zacks Investment Research · Sep 18, 2026

BTSG Faces $200M IRA Hit but Efficiency May Protect ProfitabilityBrightSpring Health Services' Home and Community Pharmacy segment experienced an 8% revenue decline to $540M in Q2, with the Inflation Reduction Act (IRA) accounting for approximately $50M of the impact. Despite a projected $200M revenue headwind in 2026 from IRA pricing changes, the company expects only a $15M EBITDA impact, demonstrating that operational efficiency gains from technology, automation, AI, and Lean initiatives are offsetting regulatory pressures. Peer companies Cardinal Health and CVS Health are similarly navigating IRA-driven revenue pressures while maintaining profitability through service agreements and operational improvements.Zacks Investment Research · Sep 17, 2026

Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?Cardinal Health expects fiscal 2027 IRA pricing changes to create similar revenue headwinds as 2026, but management aims to preserve compensation and maintain profitability through distribution agreements and operational efficiency. Peers BrightSpring and CVS Health also face IRA-related revenue pressure but are offsetting impacts through operational improvements and specialty pharmacy growth.Zacks Investment Research · Sep 16, 2026

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.The Motley Fool · Sep 14, 2026

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?The article compares Amgen, an established biotech giant with $36.7B in revenue and strong profitability, against Revolution Medicines, a clinical-stage oncology company with no approved products but a breakthrough cancer therapy (Daraxonrasib) that showed 50%+ reduction in death risk for metastatic pancreatic cancer. The author recommends Revolution Medicines for long-term investors willing to accept biotech risk, citing the paradigm-shifting potential of its RAS-targeted cancer pipeline, despite current losses and competitive pressures.The Motley Fool · Sep 11, 2026

Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?Cardinal Health reported Q4 fiscal 2026 adjusted EPS of $2.91, beating consensus by 20.3%, with full-year adjusted EPS up 37% year-over-year. While revenues missed estimates, the company raised fiscal 2027 guidance to $12.40-$12.60 EPS, implying 13-15% growth. Shares have outperformed the S&P 500 over the past month, though the stock carries a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 10, 2026

Is Cardinal Health Building a New Tech-Enabled Healthcare Platform?Cardinal Health is leveraging technology investments across distribution, specialty services, and logistics to operate as a tech-enabled healthcare platform. The company integrated Sonexus into its Nuclear business web-ordering platform for end-to-end digital workflows, achieved a 99% fill rate, and plans $700 million in fiscal 2027 capital spending. Peers CONMED and Align Technology are similarly expanding their technology-driven healthcare solutions.Zacks Investment Research · Sep 8, 2026

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.The Motley Fool · Sep 4, 2026

Cencora Raises 2026 EPS Outlook as Specialty Businesses StrengthenCencora (COR) raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 following stronger-than-expected third-quarter results. The company's U.S. segment profit grew 15.9% driven by specialty sales and GLP-1 demand, while international operating income rose 20.8%. However, headwinds from lower-margin GLP-1 products, manufacturer price reductions, and higher financing costs tempered upside. The stock maintains a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 3, 2026

to start trading

CA

CAHCardinal Health, Inc.

CAH

Pay with—

Available Balance0.00

Your PositionYou don't own any CAH yet.

Related Tickers

Earnings

Dividends

Ex Oct 1

Amount$0.52

PaysOct 15

Last · Jul 1Quarterly

Amount$0.52

Yield0.91%

Annual$2.05